Sarepta Therapeutics Inc (SRPT)
114.23
+3.73
(+3.38%)
USD |
NASDAQ |
Nov 22, 16:00
114.23
0.00 (0.00%)
After-Hours: 20:00
Sarepta Therapeutics Cash from Financing (Quarterly): 13.76M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 13.76M |
| June 30, 2024 | 39.92M |
| March 31, 2024 | 22.14M |
| December 31, 2023 | 1.943M |
| September 30, 2023 | 15.40M |
| June 30, 2023 | 5.861M |
| March 31, 2023 | 101.80M |
| December 31, 2022 | 10.75M |
| September 30, 2022 | 216.43M |
| June 30, 2022 | 0.339M |
| March 31, 2022 | 4.99M |
| December 31, 2021 | 549.25M |
| September 30, 2021 | 5.902M |
| June 30, 2021 | 3.526M |
| March 31, 2021 | 2.893M |
| December 31, 2020 | 326.94M |
| September 30, 2020 | 18.79M |
| June 30, 2020 | 17.58M |
| March 31, 2020 | 319.02M |
| December 31, 2019 | 256.97M |
| September 30, 2019 | 1.733M |
| June 30, 2019 | 6.292M |
| March 31, 2019 | 377.56M |
| December 31, 2018 | 521.28M |
| September 30, 2018 | -23.96M |
| Date | Value |
|---|---|
| June 30, 2018 | 25.35M |
| March 31, 2018 | 7.471M |
| December 31, 2017 | 506.81M |
| September 30, 2017 | 382.24M |
| June 30, 2017 | -1.174M |
| March 31, 2017 | 0.206M |
| December 31, 2016 | 7.287M |
| September 30, 2016 | 333.71M |
| June 30, 2016 | 38.17M |
| March 31, 2016 | -1.037M |
| December 31, 2015 | 125.58M |
| September 30, 2015 | 1.576M |
| June 30, 2015 | 20.25M |
| March 31, 2015 | 0.406M |
| December 31, 2014 | 0.024M |
| September 30, 2014 | 5.407M |
| June 30, 2014 | 96.03M |
| March 31, 2014 | 2.69M |
| December 31, 2013 | 1.965M |
| September 30, 2013 | 139.01M |
| June 30, 2013 | 1.721M |
| March 31, 2013 | 2.971M |
| December 31, 2012 | 157.26M |
| September 30, 2012 | 21.38M |
| June 30, 2012 | -0.021M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.339M
Minimum
Jun 2022
549.25M
Maximum
Dec 2021
96.71M
Average
16.49M
Median
Cash from Financing (Quarterly) Benchmarks
| Eli Lilly and Co | 211.30M |
| Catalyst Pharmaceuticals Inc | -5.974M |
| Regeneron Pharmaceuticals Inc | -634.00M |
| Vertex Pharmaceuticals Inc | -387.50M |
| Viking Therapeutics Inc | 2.522M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -70.70M |
| Cash from Investing (Quarterly) | -128.82M |
| Free Cash Flow | -480.40M |
| Free Cash Flow Per Share (Quarterly) | -1.075 |
| Free Cash Flow to Equity (Quarterly) | -109.21M |
| Free Cash Flow to Firm (Quarterly) | -107.96M |
| Free Cash Flow Yield | -4.18% |